AstraZeneca PLC (AZN)
| Market Cap | 251.87B -4.8% |
| Revenue (ttm) | 61.37B +8.6% |
| Net Income | 10.45B +25.9% |
| EPS | 6.68 +25.8% |
| Shares Out | 1.55B |
| PE Ratio | 23.88 |
| Forward PE | 14.85 |
| Dividend | $3.23 (2.02%) |
| Ex-Dividend Date | Aug 7, 2026 |
| Volume | 2,362,080 |
| Open | 159.12 |
| Previous Close | 158.61 |
| Day's Range | 158.53 - 161.29 |
| 52-Week Range | 153.41 - 212.71 |
| Beta | 0.21 |
| Analysts | Buy |
| Price Target | 206.91 (+29.22%) |
| Earnings Date | Oct 30, 2026 |
About AZN
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Topr... [Read more]
Financial Performance
In 2025, AstraZeneca's revenue was $58.74 billion, an increase of 8.63% compared to the previous year's $54.07 billion. Earnings were $10.23 billion, an increase of 45.34%.
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for AZN stock is "Buy." The 12-month stock price target is $206.91, which is an increase of 29.22% from the latest price.
News
Astrazeneca (AZN) Exceeds Market Returns: Some Facts to Consider
In the latest trading session, Astrazeneca (AZN) closed at $158.61, marking a +1.33% move from the previous day.
AstraZeneca price target raised to 18,600 GBp from 17,800 GBp at Citi
Citi raised the firm’s price target on AstraZeneca (AZN) to 18,600 GBp from 17,800 GBp and keeps a Buy rating on the shares.
AstraZeneca Opens New $1 Bln R&D Hub To Strengthen Global Drug Research
(RTTNews) - Global biopharmaceutical company, AstraZeneca PLC (AZN) announced that it has opened a new strategic research and development (R&D) centre in Kendall Square, Cambridge, Massachusetts.
AstraZeneca CEO Optimistic on Growth Beyond 2030 Without Major Acquisitions (NYSE: AZN)
AstraZeneca CEO Optimistic on Growth Beyond 2030 Without Major Acquisitions (NYSE: AZN)
AstraZeneca CEO says Summit drug could drive next generation of cancer combinations after $2 billion investment
AstraZeneca CEO Pascal Soriot told CNBC that Summit Therapeutics' lead drug could help power next-generation cancer combinations that could be the "future of cancer care." Soriot spoke exclusively wit...
Watch CNBC's full interview with AstraZeneca CEO Pascal Soriot
CNBC’s Annika Kim Constantino and Pascal Soriot, AstraZeneca CEO, join 'The Exchange' to discuss its $50 billion investment in stateside manufacturing and opening an research and development site in B...
AstraZeneca CEO Pascal Soriot on new Boston site: Faster, better development of new products is the hope
CNBC’s Annika Kim Constantino and Pascal Soriot, AstraZeneca CEO, join 'The Exchange' to discuss its $50 billion investment in stateside manufacturing and opening an research and development site in B...
AstraZeneca Opens New R&D Center in Cambridge, Boosting Innovation Pipeline (AZN)
AstraZeneca Opens New R&D Center in Cambridge, Boosting Innovation Pipeline (AZN)
AstraZeneca to invest over $1 billion in Massachusetts, boost workforce
AstraZeneca said on Monday it would spend more than $1 billion in Massachusetts as part of its broader $50 billion US investment plan, a move expected to expand its workforce in the state by more th...
AstraZeneca opens R&D center in Cambridge, Massachusetts
AstraZeneca (AZN) today announced the opening of its newest global strategic research and development center, in Kendall Square, Cambridge, Massachusetts. The new state-of-the-art facility builds on t...
AstraZeneca opens new global strategic R&D center in Kendall Square, Cambridge, Massachusetts
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today announced the opening of its newest global strategic research and development (R&D) center, in Kendall Square, Cambridge, Massachusetts. The new st...
Summit Therapeutics Secures $2B Strategic Investment From AstraZeneca
(RTTNews) - Summit Therapeutics Inc. (SMMT) on Monday announced the closing of AstraZeneca's (AZN) $2 billion strategic equity investment, which will support accelerated development of ivonescimab, an...
AstraZeneca completes $2B equity investment in Summit Therapeutics
Summit Therapeutics (SMMT) announced the successful closing of AstraZeneca’s (AZN) strategic equity investment in Summit. The equity investment will support continued acceleration of the development o...
AstraZeneca Completes $2 Billion Equity Investment in Summit Therapeutics
MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced the successful closing of AstraZeneca's (LSE/STO/NYSE: AZN) strategic equity investment in Summit. The equity investment...
AstraZeneca Completes $2 Billion Equity Investment in Summit Therapeutics
Summit Therapeutics Inc. (NASDAQ: SMMT) today announced the successful closing of AstraZeneca’s (LSE/STO/NYSE: AZN) strategic equity investment in Summit. The equity investment will support continued ...
AstraZeneca Stocks Moves Lower as Datroway Combination Enters Phase 3
AstraZeneca Stocks Moves Lower as Datroway Combination Enters Phase 3
Weekly Buzz: EW, ABBV, MIRM Score FDA Wins, AZN, NVO Strike Deals; LLY, KOD Report Data
(RTTNews) - The week brought a fresh round of developments across the biotech and pharma landscape, with companies advancing new therapies through regulatory milestones, clinical studies, strategic de...
AstraZeneca Trillion-Pound Valuation: Can the Pipeline Deliver It?
The debate over which UK-listed company will first achieve an AstraZeneca trillion-pound valuation, or any trillion-pound market capitalisation, has been circulating among investors for some time, but...
Summit Therapeutics enters trial collaboration with AstraZeneca, Daiichi Sankyo
Summit Therapeutics (SMMT) announced a clinical trial collaboration agreement with Daiichi Sankyo (DSNKY) and AstraZeneca (AZN) to evaluate ivonescimab, a novel, potential first-in-class investigation...
Daiichi Sankyo, AstraZeneca, Summit Partner On Datroway- Ivonescimab Cancer Studies
(RTTNews) - Daiichi Sankyo (4568.TS) and AstraZeneca (AZN) have entered into a clinical trial collaboration agreement with Summit Therapeutics (SMMT) to evaluate Datroway (datopotamab deruxtecan) in c...
Daiichi Sankyo, AstraZenca, Summit Partner To Evaluate Datroway Plus Ivonescimab
(RTTNews) - Daiichi Sankyo (4568.TS) and AstraZenca (AZN) have entered into a clinical trial collaboration agreement with Summit Therapeutics (SMMT) to evaluate Datroway (datopotamab deruxtecan) in co...
AstraZeneca, Daiichi Sankyo partner with Summit to test cancer drug combination
AstraZeneca and Daiichi Sankyo have entered into a clinical collaboration with Summit Therapeutics to test their cancer drug, Datroway, in combination with Summit's ivonescimab across multiple tum...
Daiichi Sankyo and AstraZeneca Enter into Clinical Trial Collaboration with Summit Therapeutics to Evaluate Datroway® in Combination with Ivonescimab Across Multiple Tumor Types
TOKYO--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/NYSE: AZN) have entered into a clinical trial collaboration agreement with Summit Therapeutics Inc. (Nasdaq: SMMT) to evalua...
Summit Therapeutics Announces Clinical Trial Collaboration with AstraZeneca and Daiichi Sankyo to Evaluate Ivonescimab in Combination with TROP2-Directed ADC Datroway
MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (Nasdaq: SMMT) today announced a clinical trial collaboration agreement with Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/NYSE: AZN) to evaluate...
AstraZeneca Stocks Drops as $2 Billion Buys an Oncology Option
AstraZeneca Stocks Drops as $2 Billion Buys an Oncology Option